Hardide PLC
12 August 2026
12 August 2026
Hardide plc
("Hardide" or "the Company")
Capital Reduction Approved
Hardide plc (AIM: HDD), the developer and provider of advanced surface coating technology, announces that the reduction of capital approved by shareholders at the General Meeting of the Company held on 21 July 2026 (the “Capital Reduction”) has been approved by the High Court of Justice of England and Wales (the“Court”).
The Court order approving the Capital Reduction and a statement of capital approved by the Court have each been registered with the Registrar of Companies and accordingly, the Capital Reduction has now become effective.
|
For further information: |
|
|
Hardide plc Matt Hamblin (CEO) Simon Hallam (Finance Director)
|
Tel: +44 (0) 1869 353 830 |
|
Cavendish Capital Markets Ltd - Nominated Adviser and Broker Henrik Persson / Elysia Bough (Corporate Finance) Jasper Berry / Dale Bellis (Sales)
|
Tel: +44 (0) 2072 200 500 |
|
IFC Advisory Graham Herring Tim Metcalfe
|
Tel: +44 (0) 20 3934 6633 |
Notes to editors:
Hardide develops, manufactures and applies advanced technology tungsten carbide/tungsten metal matrix coatings to a wide range of engineering components. Its patented technology is unique in combining in one material, a mix of toughness and resistance to abrasion, erosion and corrosion; together with the ability to coat accurately interior surfaces and complex geometries. The material is proven to offer dramatic improvements in component life, particularly when applied to components that operate in very aggressive environments. This results in cost savings through reduced downtime and increased operational efficiency as well as a reduced carbon footprint. Customers include leading companies operating in the energy sectors, valve and pump manufacturing, industrial gas turbine, precision engineering and aerospace industries.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.